Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer

作者：Xie Xiaoqi; Kerrigan John E; Minko Tamara; Garbuzenko Olga; Lee Kuo Chieh; Scarborough Alex; Abali Emine Ercikan; Budak Alpdogan Tulin; Johnson Farley Nadine; Banerjee Debabrata; Scotto Kathleen W; Bertino Joseph R^*

来源：Cancer Biology and Therapy, 2013, 14(8): 742-751.

DOI：10.4161/cbt.25184

• E2F-1
• penetratin peptide
• small cell lung cancer
• pegylated liposomes
• mouse xenografts

E2F-1, a key transcription factor necessary for cell growth, DNA repair, and differentiation, is an attractive target for development of anticancer drugs in tumors that are E2F oncogene addicted. We identified a peptide isolated from phage clones that bound tightly to the E2F-1 promoter consensus sequence. The peptide was coupled to penetratin to enhance cellular uptake. Modeling of the penetratin-peptide (PEP) binding to the DNA E2F-1 promoter demonstrated favorable interactions that also involved the participation of most of the penetratin sequence. The penetratin-peptide (PEP) demonstrated potent in vitro cytotoxic effects against a range of cancer cell lines, particularly against Burkitt lymphoma cells and small cell lung cancer (SCLC) cells. Further studies in the H-69 SCLC cell line showed that the PEP inhibited transcription of E2F-1 and also several important E2F-regulated enzymes involved in DNA synthesis, namely, thymidylate synthase, thymidine kinase, and ribonucleotide reductase. As the PEP was found to be relatively unstable in serum, it was encapsulated in PEGylated liposomes for in vivo studies. Treatment of mice bearing the human small cell lung carcinoma H-69 with the PEP encapsulated in PEGylated liposomes (PL-PEP) caused tumor regression without significant toxicity. The liposome encapsulated PEP has promise as an antitumor agent, alone or in combination with inhibitors of DNA synthesis.

• 出版日期2013-8-1